Recurrent Squamous Cell Carcinoma of the Larynx Completed Phase 2 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01044433Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckTreatment